Chemistry: analytical and immunological testing – Involving production or treatment of antibody
Reexamination Certificate
2004-02-02
2011-11-29
Wang, Chang-Yu (Department: 1649)
Chemistry: analytical and immunological testing
Involving production or treatment of antibody
C436S548000, C436S543000, C436S544000, C436S545000, C436S546000, C424S130100, C424S141100, C424S142100, C530S388100
Reexamination Certificate
active
08067247
ABSTRACT:
The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
REFERENCES:
patent: 6576754 (2003-06-01), Hall et al.
patent: 6635742 (2003-10-01), Boyle et al.
patent: 2003/0158402 (2003-08-01), Hall et al.
patent: WO-93/14125 (1993-07-01), None
patent: WO 93/14125 (1993-07-01), None
patent: WO 95/07706 (1995-03-01), None
patent: WO 97/17368 (1997-05-01), None
't Hart et al. Curr. Opin. Neurol. 2003. 16: 375-383.
Burgess et al. J of Cell Bio. 111:2129-2138, 1990.
Pawson et al. 2003, Science 300:445-452.
Campbell et al. Neuron. 2006, 52:77-92.
Kumanogoh, et al, “Class IV semaphoring Sema4A enhances T-cell activation and interacts with Tim-2” Oct. 10, 2002, pp. 629-933, vol. 419, No. 6907, Nature, London.
Herold et al, “Activation signals are delivered through two distinct epitopes of CD100, a unique 150 kDa human lymphocyte surface structure previously defined by BB18 Ab”, 1995, pp. 1-8, vol. 7, No. 1, International Immunology.
Goldsby, et al, “Kuby Immunology, 4th ed.”, 2000, p. 502 & 504.
Levin, et al, “Molecular mimicry to neurons results in neurological disease”, 2002, pages Abstract No. 415.3, vol. 2002, 32nd Annual meeting of the society for neuroscience, Orlando, FL.
Wang, et al, “Functional soluble CD100/Sema4D released from activated lymphocytes: Possible role in normal and pathologic immune responses”, Jun. 1, 2001, pp. 3498-3504, vol. 97, No. 11, Blood, W.B. Saunders Company, Orlando, FL.
Delaire, et al, “Inhibition of immune cell migration by soluble CD100 and H-Sema Iiisemaphorins”, Jun. 20, 2000, p. 103, vol. 55, No. SUPPL 1, Tissue Antigens, Munksgaard, Copenhagen, DK.
Kumanogoh, et al, “The CD100-CD72 interaction: a novel mechanism of immune regulation”, Dec. 1, 2001, pp. 670-676, vol. 22, No. 12, Trends in Immunology, Elsevier, Cambridge, GB.
Kumanogoh, et al “Requirement for the lymphocyte semaphoring, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells”, Aug. 1, 2002, pp. 1175-1181, vol. 169, No. 3, Journal of Immunology.
Giraudon, et al “Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells”, Jan. 15, 2004, pp. 1246-1255, vol. 172, No. 2, Journal of Immunology.
Delaire, S., et al., “Inhibition of Immune Cell Migration by Soluble CD100 and HSema III Semaphorins,”Tissue Antigens, 2000, p. 103, vol. 55(Suppl. 1).
Giraudon, P., et al., “Semaphorin CD100 from Activated T Lymphocytes Induces Process Extension Collapse in Oligodendrocytes and Death of Immature Neural Cells,”Journal of Immunology, 2004, pp. 1246-1255, vol. 172(2).
Goldsby, R., et al., “Autoimmunity,”Kuby Immunology, 4th ed., 2000, pp. 502-504, W.H. Freeman and Company, USA.
Herold, C., et al., “Activation Signals Are Delivered Through Two Distinct Epitopes of CD100, a Unque 150 kDa Human Lymphocyte Surface Structure Previously Defined by BB18 mAb,”International Immunology, 1995, pp. 1-8, vol. 7(1).
Kumanogoh, A., and H. Kikutani, “The CD100-CD72 Interaction: A Novel Mechanism of Immune Regulation,”Trends in Immunology, 2001, pp. 670-676, vol. 22(12).
Kumanogoh, A., et al., “Class IV Semaphorin Sema4A Enhances T-Cell Activation and Interacts with Tim-2,”Nature, 2002, pp. 629-633, vol. 419(6907).
Kumanogoh, A., et al., “Requirement for the Lymphocyte Semsphorin, CD100, in the Induction of Antigen-Specific T Cells and the Maturation of Dendritic Cells,”Journal of Immunology, 2002, pp. 1175-1181, vol. 169(3).
Levin, M.C., et al., “Molecular Mimicry to Neurons Results in Neurological Disease,”Society for Neuroscience Abstract Viewer and Itinerary Planner, 2002, Abstract No. 415.3, vol. 2002.
Wang, X., et al., “Functional Soluble CD100/Sema4D Released from Activated Lymphocytes: Possible Role in Normal and Pathologic Immune Responses,”Blood, 2001, pp. 3498-3504, vol. 97(11).
Billard, C., et al., “Switch in the Protein Tyrosine Phosphatase Associated with Human CD100 Semaphorin at Terminal B-Cell Differentiation Stage,”Blood, 2000, pp. 965-972, vol. 95(3).
Bougeret, C., et al., “Increased Surface Expression of a Newly Identified 150-kDa Dimer Early After Human T Lymphocyte Activation,”The Journal of Immunology, 1992, pp. 318-323, vol. 148(2).
Delaire, S., et al., “Biological Activity of Soluble CD100. II. Soluble CD100, Similarly to H-SemaIII, Inhibits Immune Cell Migration,”The Journal of Immunology, 2001, pp. 4348-4354, vol. 166.
Elhabazi, A., et al., “The Human Semphorin-Like Leukocyte Cell Surface Molecule CD100 Associates with a Serine Kinase Activity,”The Journal of Biological Chemistry, 1997, pp. 23515-23520, vol. 272(38).
Elhabazi, A., et al., “Structure and Function of the Immune Semaphorin CD100/SEMA4D,”Critical Reviews™ in Immunology, 2003, pp. 65-81, vol. 23(1&2).
Gauld, S., et al., “B Cell Antigen Receptor Signaling: Roles in Cell Development and Disease,”Science, 2002, pp. 1641-1642, vol. 296.
Hall, K., et al., “Human CD100, A Novel Leukocyte Semaphorin ThatPromotes B-Cell Aggregation and Differentiation,”Immunology, 1996, pp. 11780-11785, vol. 93.
Herold, C., et al., “CD100 Defines a Newly Identified 150-kDa Human Lymphocyte Surface Structure,” 1994, In Schlossman, S. et al., eds.Leukocyte Typing V, Section T, Oxford University Press, Oxford.
Ishida, I., et al., “Involvement of CD100, A Lymphocyte Semaphorin, in the Activation of the Human Immune System Via CD72: Implications for the Regulation of Immune and Inflammatory Responses,”International Immunology, 2003, pp. 1027-1034, vol. 15(8).
Kumanogoh, A. and H. Kikutani, “Immune Semaphorins: A New Area of Semaphorin Research,”Journal of Cell Science, 2003, pp. 3463-3470, vol. 116.
Shi, W., et al., “The Class IV Semaphorin CD100 Plays Nonredundant Roles in the Immune System: Defective B and T Cell Activation in CD100-Deficient Mice,”Immunity, 2000, pp. 633-642, vol. 13.
Watanabe, C., et al., “Enhanced Immune Respones in Transgenic Mice Expressing a Truncated Form of the Lymphoctye Semaphorin CD100,”The Journal of Immunology, 2001, pp. 4321-4328, vol. 167.
Zhu, L., et al., “Semaphorin 4D (CD100) is Expressed on the Surface of Human Platelets and Proteolytically Shed During Platelet Activation,”Blood, 2003, vol. 102(11).
Elhabazi, A., et al., “Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 is Released from the Surface of T Lymphocytes by Regulated Proteolysis,”The Journal of Immunology, 2001, pp. 4341-4347, vol. 166.
Belin Marie-Françoise
Bensussan Armand
Boumsell Laurence
Giraudon Pascale
Alston & Bird LLP
Institut National de la Sante Et de la Recherche Medicale (INSER
Wang Chang-Yu
LandOfFree
Use of anti-CD100 antibodies for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-CD100 antibodies for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-CD100 antibodies for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287520